Zalcitabine (Zalcitabine)
Overview of Zalcitabine
Zalcitabine is a synthetic pyrimidine nucleoside possessing antiretroviral properties. In June 1992, it became the third agent to be approved by the FDA for the treatment of HIV infection. It prevents the replication of the human immunodeficiency virus (HIV) involved in acquired immunodeficiency syndrome (AIDS). However, because monotherapy with zalcitabine has been shown to be inferior to monotherapy with zidovudine (AZT), zalcitabine was approved for use only in combination with zidovudine. In addition, zalcitabine was given a priority review by the FDA; approval was based on improvements in CD4 counts and not demonstration of clinical efficacy. In February 1996, zalcitabine was granted full FDA approval based on data from two randomized, double-blind clinical studies.
Indication of Zalcitabine
Zalcitabine is primarily indicated in conditions like Epidural block, surgery, HIV infection.
Contraindication of Zalcitabine
No data regarding the contra indications of Zalcitabine is available.
Side Effects of Zalcitabine
The severe or irreversible adverse effects of Zalcitabine, which give rise to further complications include Tachycardia, Hepatitis, Jaundice, Seizures, Hypertension, Syncope, Hyperbilirubinemia, Hepatic failure.,The symptomatic adverse reactions produced by Zalcitabine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Headache, Nausea, Anorexia, Fever, Myalgia, Malaise, Peripheral neuropathy, Weight loss, Chest pain, Hypoglycemia, Hyponatremia.
Precautions of Zalcitabine
Zalcitabine should be used with extreme caution during pregnancy. It is not recommended during pregnancy. It should be used with extreme caution in patients with history of pancreatic disease or tingling of the hands or feet (called peripheral neuropathy), history of heart trouble, kidney or liver disease. Food decreases the absorption of the drug. Follow doctor's instructions exactly regarding how to take it.